Cyclo Therapeutics, Inc. (CYTH)
Fuera de horario:
Cyclo Therapeutics, Inc.
6714 NW 16th Street
Suite B
Gainesville, FL 32653
United States
386 418 8060
https://cyclotherapeutics.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. N. Scott Fine | CEO & Director | 569.92k | N/D | 1957 |
| Mr. C. E Strattan | Founder & Director | N/D | N/D | 1946 |
| Mr. Joshua M. Fine | CFO & Secretary | 421.17k | N/D | 1982 |
| Mr. Michael Eric Lisjak | Global Head of Regulatory Affairs & Senior VP of Business Development | 430.4k | N/D | 1974 |
| Dr. Jeffrey L. Tate Ph.D. | COO, Chief Quality Officer & Director | 255.14k | N/D | 1958 |
| Ms. Lori McKenna | Global Head of Patient Advocacy | N/D | N/D | N/D |
| Dr. Karen Mullen FFPM | Interim Chief Medical Officer | N/D | N/D | N/D |
Descripción
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Cyclo Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
